Table 3.
Three multivariate Cox models for alcohol drinking status on overall survival and disease–free survival among patients with esophageal carcinoma
| Model A adjusted for baseline covariates† | Model B adjusted for baseline covariates† and smoking | Model C adjusted for baseline covariates,†smoking, and gender | |
|---|---|---|---|
| Overall survival | |||
| Drinking status (ever vs never) | 1.30 (1.14–1.47, P < 0.001) | 1.24 (1.08–1.43, P = 0.002) | 1.22 (1.06–1.41, P = 0.005) |
| Age, years (>60 vs ≤60) | 1.22 (1.08–1.38,P = 0.002) | 1.22 (1.08–1.39, P = 0.001) | 1.23 (1.08–1.39, P = 0.001) |
| Weight loss (yes vs no) | 1.18 (1.04–1.33, P = 0.009) | 1.18 (1.04–1.33, P = 0.009) | 1.18 (1.05–1.34, P = 0.007) |
| AJCC stage | |||
| 0+ I | 1.00 | 1.00 | 1.00 |
| II | 2.08 (1.52–2.85, P < 0.001) | 2.08 (1.52–2.85, P < 0.001) | 2.09 (1.53–2.86, P < 0.001) |
| III | 4.49 (3.28–6.14, P < 0.001) | 4.46 (3.26–6.10, P < 0.001) | 4.46 (3.26–6.11, P < 0.001) |
| Radicality of surgery (R1 + R2 vs R0) | 2.14 (1.72–2.66, P < 0.001) | 2.16 (1.74–2.68, P < 0.001) | 2.17 (1.75–2.70, P < 0.001) |
| Adjuvant treatment | |||
| None | 1.00 | 1.00 | 1.00 |
| Chemotherapy | 0.71 (0.59–0.87, P = 0.001) | 0.72 (0.59–0.87, P = 0.001) | 0.71 (0.58–0.86, P = 0.708) |
| Radiotherapy | 1.04 (0.80–1.35, P = 0.792) | 1.03 (0.79,1.34, P = 0.812) | 1.02 (0.78–1.32, P = 0.907) |
| Chemoradiotherapy | 0.88 (0.60–1.30, P = 0.521) | 0.89 (0.60–1.31, P = 0.131) | 0.88 (0.60–1.30, P = 0.525) |
| Smoking status (ever vs never) | 1.12 (0.97–1.29, P = 0.131) | 1.02 (0.85–1.22, P = 0.836) | |
| Gender (female vs male) | 0.85 (0.69–1.05, P = 0.124) | ||
| Disease-free survival | |||
| Drinking status (ever vs never) | 1.22 (1.07–1.39, P = 0.002) | 1.17 (1.012–1.35, P = 0.027) | 1.16 (1.01–1.34, P = 0.037) |
| Age, years (>60 vs ≤60) | 1.19 (1.05–1.34, P = 0.006) | 1.19 (1.05–1.34, P = 0.006) | 1.19 (1.05–1.34, P = 0.004) |
| Weight loss (yes vs no) | 1.12 (0.99–1.26, P = 0.073) | 1.12 (0.99–1.26, P = 0.072) | 1.12 (0.99–1.27, P = 0.067) |
| AJCC stage | |||
| 0+ I | 1.00 | 1.00 | 1.00 |
| II | 2.21 (1.62–3.00, P < 0.001) | 2.21 (1.63–3.01, P < 0.001) | 2.22 (1.63–3.01, P < 0.001) |
| III | 4.75 (3.49–6.46, P < 0.001) | 4.72 (3.47–6.43, P < 0.001) | 4.73 (3.47–6.43, P < 0.001) |
| Radicality of surgery (R1+ R2 vs R0) | 1.78 (1.43–2.22, P < 0.001) | 1.78 (1.43–2.22, P < 0.001) | 1.79 (1.44–2.24, P < 0.001) |
| Adjuvant treatment | |||
| None | 1.00 | 1.00 | 1.00 |
| Chemotherapy | 0.83 (0.68–1.01, P = 0.056) | 0.83 (0.69–1.01, P = 0.062) | 0.83 (0.68–1.00, P = 0.055) |
| Radiotherapy | 1.12 (0.86–1.45, P = 0.409) | 1.11 (0.86–1.45, P = 0.426) | 1.10 (0.85–1.44, P = 0.466) |
| Chemoradiotherapy | 0.87 (0.59–1.30, P = 0.508) | 0.89 (0.0–1.32, P = 0.548) | 0.88 (0.59–1.31, P = 0.533) |
| Smoking status (ever vs never) | 1.11 (0.97–1.28, P = 0.144) | 1.06 (0.88–1.27, P = 0.563) | |
| Gender (female vs male) | 0.91 (0.74–1.12, P = 0.392) | ||
AJCC, American Joint Committee on Cancer.
†
Baseline covariates include age, weight loss, stage, radicality of surgery, and adjuvant treatment.